https://www.patientcareonline.com/view/idweek-2023-nirsevimab-efficacy-against-rsv-lrti-associated-hospitalization-is-robust-across-infant-subgroups
0
0
IDWeek 2023: Nirsevimab Efficacy Against RSV-LRTI-Associated Hospitalization is Robust Across Infant Subgroups - Patient Care Online
10/14/23 at 2:44pm
Organization
Patientcareonline.com
Author
Grace Halsey
Details
37 words
Summarize
Health Family Nirsevimab Efficacy Against RSV-LRTI-Associated Hospitalization RSV infant subgroups
IDWeek 2023. Nirsevimab efficacy was significant across infant subgroups in preventing hospitalization for RSV-LRTI during a first RSV season.
Create an account or login to join the discussion